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INTRODUCTION
Neonatal mortality accounts for two-thirds of the infant mortality rate in India and other developing 
countries.1 It is estimated that over 1 million newborn infants die during the first four weeks of life.2 
The current neonatal mortality rate in India is 39 per 1000 live births.1 Asphyxia was the single most 
important cause of still-births, accounting for 45.1% of all intrauterine deaths and the primary 
cause for neonatal mortality, accounting for 28.8% of all the deaths.2 Morbidity associated 
with  perinatal  asphyxia  includes  cerebral  palsy,  learning  disabilities,  visual  and  hearing 
impairments,  behavioural  abnormalities and residual  motor  or  cognitive disabilities.  These 
have a considerable effect on the surviving babies, their families and on society.3,4
The etiology of perinatal Hypoxic Ischemic Encephalopathy (HIE) includes those conditions 
that can affect the cerebral blood flow in the fetus and newborn compromising the supply of 
oxygen to the brain. They may develop antepartum (20%), intrapartum (30%), intrapartum 
and antepartum (35%) or postpartum (10%).3 HIE that develops in the setting of perinatal 
asphyxia is part of a multiorgan system disease.5
After an asphyxial event, there may be an opportunity to intervene to minimize brain damage. The first 
phase of brain damage, early cell death, results from the primary exhaustion of cellular energy stores. 
Early cell death can occur within minutes. Damage to the brain is limited at this stage by immediate 
resuscitation to restore oxygen supply and blood circulation. A secondary phase of neuronal injury 
occurs  some times  after  the  initial  insult.  There  are  several  mechanisms  involved in  this  process. 
Treatment during the post resuscitation phase aim to block these processes thereby limiting secondary 
cell damage and minimizing the extent of potential brain damage.
Neuroprotection was achieved in animal models of brain ischemia by reduction in brain temperature by 
2°C to 5°C.6-11 Randomized control trials done in the developed countries using expensive equipment 
was shown to reduce mortality and morbidity among newborn survivors of perinatal asphyxia.12-17 The 
present  trial  was  conducted  to  evaluate  whether  whole-body cooling  could  be  achieved in  a  low-
resource setting using simple available cooling materials.
AIM AND OBJECTIVES
Aim and objectives
To study the feasibility of whole body cooling for newborn infants with perinatal asphyxia in a low 
resource setting.
Primary objective
Achievement of target temperature within 1 hour of initiation of treatment and within 6 hours of birth 
and maintaining the target temperature for 72 hours.
Secondary objectives
Monitoring  adverse  events  and  possible  complications  that  could  occur  secondary  to  whole  body 
cooling
1. Cardiac arrhythmia 
2. Persistent hypoxemia 
3. Hypotension despite full inotropic support 
4. Skin changes 
5. Thrombocytopenia 
6. Life threatening coagulopathy 
7. Arterial thrombosis
8. Hepatic and renal failure
9. Electrolyte disturbances
10. Death
LITERATURE REVIEW
Encephalopathy  following  perinatal  asphyxia  is  the  most  common  neurologic  disease  during  the 
neonatal period (hypoxic ischemic encephalopathy, HIE). It is associated with a high mortality and 
morbidity including cerebral  palsy,  mental  retardation,  visual  and hearing impairment,  behavioural 
abnormalities and seizures. The incidence of HIE is 1.0-1.5% in most centers and is usually related to 
the gestational age and birth weight.18
Definition of perinatal asphyxia
There is no gold standard definition of perinatal asphyxia that exists to date. 
The WHO defines perinatal asphyxia as a “failure to initiate and sustain breathing at birth”.19 
NNPD defines birth asphyxia2 as
Definition I
• Moderate birth asphyxia: Slow gasping breathing at 1-minute of age.
• Severe birth asphyxia: No breathing at 1-minute of age.
Definition II
• Birth asphyxia: Apgar score of <7 at 1-minute of age.
• Moderate birth asphyxia: Apgar score of 4-6 at 1-minute of age.
• Severe birth asphyxia: Apgar score of <3 at 1-minute of age.
For HRRC sites: cry after 5 minutes of age or no cry at all.
The American Academy of Pediatrics (AAP) and the American College of Obstetrics and Gynecology 
(ACOG) criteria states that all of the following must be present for diagnosis of asphyxia20
i. Profound metabolic or mixed academia (pH < 7.00) in cord arterial blood
ii. Persistence of Apgar scores 0-3 for >5 minutes
iii. Neonatal neurologic sequelae (seizures, coma, hypotonia)
iv. Multiple organ involvement (kidneys, lungs, liver, heart intestine)
Pathogenesis of hypoxic ischemic brain injury
Impaired  cerebral  blood  flow  is  the  predominant  pathogenetic  mechanism  underlying  the 
neuropathology  attributed  to  intrapartum  hypoxia-ischemia.  This  is  most  likely  to  occur  as  a 
consequence of interruption in placental blood flow and gas exchange causing severe fetal acidemia 
which is defined as a fetal umbilical arterial pH of <7.00.21 Hypoxia ischemia is associated with two 
phases of pathologic events that culminate in brain injury (Fig 1.). These phases are the primary and 
secondary energy failure  based on the characteristics  of the cerebral  energy states as  described in 
experimental animals. 
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FIGURE 1: Potential pathways for brain injury after hypoxia-ischemia.
Primary  energy  failure  is  characterized  by  reductions  in  the  cerebral  blood  flow  and 
oxygen/substrates.22 At  the  cellular  level,  the  oxygen  depletion  results  in  a  switch  to  anaerobic 
metabolism with rapid depletion of high energy phosphate reserves and accumulation of lactic acid 
resulting in tissue acidosis.23 Transcellular  ion-pump failure results in intracellular  accumulation of 
Na+, Ca++ and water (cytotoxic edema) causing osmotic dysregulation. Excitatory neurotransmitters, 
specifically  glutamate,  are  released  as  a  result  of  membrane  depolarization  from axon  terminals. 
Glutamate then activates specific cell surface receptors resulting in further influx of Na+ and Ca++ into 
postsynaptic  neurons.  The  free  fatty  acid  that  accumulates  in  the  cell  secondary  to  membrane 
phospholipids turnover, undergo peroxidation by oxygen free radicals. Ca++ ions accumulate within the 
cytoplasm as a consequence of increased cellular influx as well as decreased efflux across the plasma 
membrane combined with release from mitochondria and endoplasmic reticulum. In selected neurons, 
the intracellular calcium induces the production of nitric oxide, a free radical that diffuses into adjacent 
cells that are susceptible to nitric-oxide toxicity. Elevation in intracellular Ca++ triggers a number of 
destructive pathways by activating lipases, proteases and endonucleases.23  The combined effects of 
cellular energy failure, acidosis, glutamate release, intracellular Ca++ accumulation, lipid peroxidation, 
and nitric-oxide neurotoxicity serve to disrupt essential components of the cell, which ultimately lead 
to cell death. Many factors, including the duration or severity of the insult, influence the progression of 
cellular injury after hypoxia-ischemia.23
After  adequate  resuscitation,  that  may occur  in  utero or  postnatally in  the delivery room, cerebral 
oxygenation and perfusion are restored.  Resolution of the hypoxia ischemia within a specific time 
interval reverses the fall in high energy phosphorylated metabolites and intracellular pH and promotes 
recycling of receptors.  The duration of time for  hypoxia ischemia to  be successfully reversed and 
promote recovery will be affected by maturation, preconditiong events, substrate availablility, body 
temperature and simultaneous disease process.23
However, the process of cerebral energy failure recurs from 6 to 48 hours later in a second phase of 
injury.  This  phase  is  characterized  by a  decrease  in  the  ratio  of  phosphocreatinine  and adenosine 
triphosphate with an unchanged intracellular pH and stable cardio-respiratory status and contributes to 
additional brain injury.25,26 The presence and severity of secondary energy failure depends on the extent 
of primary energy failure. The pathogenesis of the secondary energy failure is not as well understood as 
the  primary  energy  failure,  but  likely  involves  multiple  pathophysiologic  processes  including 
accumulation  of  excitatory neurotransmitters,  oxidative  injury,  apoptosis,  inflammation  and altered 
growth  factors  and  protein  synthesis.23 Evidence  suggests  that  circulatory  and  endogenous 
inflammatory cells and mediators also contribute to the ongoing brain injury. In human infants, the 
severity of the secondary energy failure is correlated with adverse neuro-developmental outcome at 1 
and 4 years.22
The mechanism of neuronal cell death in animals and humans after hypoxia-ischemia includes neuronal 
necrosis and apoptosis. The intensity of the initial insult may determine the mode of death, with severe 
injury resulting in necrosis, whereas milder insults result in apoptosis. Because the mechanisms of 
neuronal necrosis versus apoptosis likely differ, strategies to minimize brain damage in an affected 
infant after hypoxia-ischemia likely will have to include interventions that target both processes.24
There is a latent phase in the time interval between the primary and the secondary energy failure that 
corresponds to  the therapeutic  window. The duration of  the therapeutic  window in near-term fetal 
sheep is approximately 6 hours.  Initiation of therapies in the therapeutic window has been successful 
in reducing brain damage.9,10
Current therapies for neonatal hypoxic-ischemic encephalopathy
The management of neonates with HIE has been limited to supportive intensive care that  includes 
correction  of  hemodynamic  and  pulmonary  disturbances,  correction  of  metabolic  disturbances, 
treatment of seizures if present and monitoring for other organ dysunction.18 Brain specific therapies 
have been developed over the last 15 years with the objective to attenuate components of the cascade of 
events  triggered  by  hypoxia  ischemia.23 For  a  therapy  to  be  applicable  in  the  clinical  field,  the 
neuroprotective agent should have the following characteristics: It should target specific mechanisms 
mediating pathogenesis of tissue injury. It should be initiated with ease within a limited interval of time 
after the onset of injury. The therapy should be maintained for the duration needed to optimize the 
neuroprotective effect and it should be free of adverse effects.23 
Pharmacologic agents that are under experimental investigation
1. Oxygen free radical inhibitors and scavengers
Oxygen-free  radicals  are  generated  during and after  hypoxia–ischemia  in  several  ways.  First,  free 
radicals are produced within mitochondria when cytochrome oxidase is not fully saturated with oxygen, 
thereby liberating free radicals at more proximal steps. These oxygen-free radicals cannot be consumed 
further and leak out into the cytoplasm. Other sources of oxygen-free radicals during hypoxia–ischemia 
and  especially  during  the  reperfusion  interval  of  recovery  are  as  by-products  in  the  synthesis  of 
prostaglandins from arachidonic acid and the conversion of hypoxanthine to xanthine and uric acid.22
Free radicals and reactive oxygen species (superoxide and hydrogen peroxide) cause tissue injury only 
when the radicals exceed the brain’s endogenous antioxidant defenses. The newborn human infant, 
especially the premature infant, might be particularly susceptible to free radical injury because of a 
relative  deficiency  in  the  brain’s  antioxidants,  including  the  enzymes  superoxide  dismutase  and 
glutathione peroxidase.22 Recent evidence also suggests that circulating and endogenous inflammatory 
cells  act  as  mediators  of  hypoxic–ischemic  injury in  the  immature  brain,  presumably through the 
production of oxygen-free radicals.27
Antioxidant enzymes superoxide dismutase and catalase conjugated to polyethylene glycol has been 
shown to reduce hypoxic-ischemic brain damage and maintain the stability of the blood brain barrier. 
However, these enzymes have a narrow therapeutic dosage range and are generally protective only 
when administered many hours after the hypoxic-ischemic insult. The prolonged time taken for the 
conjugated enzymes to penetrate the blood brain barrier into brain parenchyma precludes their clinical 
usefulness in reperfusion injury.28
Xanthine oxidase inhibitors /scavengers (allopurinol and oxypurinol) inhibit specific reactions in the 
production of prostaglandins and xanthine, the formation of which involves the generation of oxygen-
free radicals. These drugs protect immature rats from hypoxic-ischemic brain damage if administered 
early during the recovery phase of resuscitation.29 Randomized control trials  comparing allopurinol 
with either  no treatment30 or  placebo31 showed no significant  difference between treatments  in  the 
composite outcome of rate of death or developmental delay. 
Studies done on  Miltiorrhizae  (a Chinese herb with antioxidative properties) and citicholine (also an 
antioxidant)  showed that  miltiorrhizae significantly reduced the combined outcome of mortality or 
neurological abnormality, the trial gave insufficient information to determine trial quality and validity 
of the findings. There was no information available on the adverse effects.30,31
Indomethacin,  a  cyclooxygenase  and  phospholipase  inhibitor,  has  been  shown  to  decrease  brain 
damage in experimental animals by reducing the formation of free radicals.32
21 aminosteroids (lazeroids) have been shown to be neuroptrotective in experimental animal models of 
hypoxia-ischemia  by  scavenging  the  peroxyl  radicals  thus  preventing  the  Fe-dependant  lipid 
peroxidation. Their site of action is within cerebral blood vessels, thereby reducing reperfusion injury.33 
Platelet-activating factor, a potent phospholipid inflammatory mediator, is synthesized in the brain, and 
its concentration is increased during cerebral ischemia. Liu et al have shown in immature rats that the 
platelet-activating factor antagonist BN 52021 attenuates hypoxic–ischemic brain damage.34
2. Excitatory amino acid antagonists
Research in experimental animals has implicated a role for the excitatory amino acid glutamate in the 
production of hypoxic–ischemic brain damage in the immature and adult  brain.  First,  glutamate is 
directly toxic to mature neurons in culture. Second, neurons in culture and hippocampal slices die on 
exposure to anoxia, but their death can be prevented by the presence of magnesium, which blocks 
glutamate receptors within the calcium ion channel, or by specific glutamate antagonists. Third, direct 
injection of glutamate or glutamate agonists into specific regions of brain in vivo produces neuronal 
injury  identical  to  that  seen  after  hypoxia-ischemia.  Fourth,  deafferentation  of  the  glutaminergic 
excitatory  input  into  the  hippocampus  reduces  the  damage  produced  by  hypoxia–ischemia.  These 
studies  provide  convincing  evidence  that  excessive  exposure  of  neurons  to  glutamate,  leads  to 
morphologic alterations characteristic of ischemic neuronal necrosis.34
Available  excitatory  amino  acid  antagonists  include  phencyclidine,  dextromethorphan,  ketamine, 
MK-801, and NBQX, among others. These compounds have been found efficacious in reducing the 
extent of hypoxic–ischemic brain damage in adult animals even when administered up to 24 hours after 
the metabolic insult.34
Magnesium acts as a glutamate receptor antagonist in that it  blocks the neuronal influx of calcium 
within the ion channel. Magnesium sulfate has been shown to reduce the severity of hypoxic–ischemic 
brain  damage  in  immature  rats.35 One  systematic  review  identified  no  RCTs  on  the  effects  of 
magnesium sulphate in infants with asphyxia. Limited evidence from one small RCT found that, when 
assessing reductions  in the composite  adverse outcome of  survival,  abnormal  cranial  computerised 
tomography and electroencephalography results, and failure to establish oral feeding by 14 days of age, 
magnesium sulphate/dopamine combination was more effective than no drug treatment. The RCT was 
underpowered  to  detect  significant  differences  between  groups  when  outcomes  were  assessed 
separately. The RCT gave no report on adverse outcomes.4
 
3. Calcium channel blockers
Increase in the intracellular calcium ion concentration to dangerous levels can cause neurotoxicity and 
neuronal damage.22 Calcium channel blockers like flunarizine and nimodipine, reduce the extent of 
hypoxic brain damage by inhibiting the calcium ion influx into the neurons.35 However in the clinical 
setting, Levene et al37 showed a mean increase in heart rate with a decrease in the mean blood pressure 
in newborn infants after the administration of nicardipine thus limiting their potential toxicity.
4. Inhibitors of nitric-oxide production
The free radical gas nitric oxide is involved in a cascade of metabolic events by reacting with other free 
radicals to form even more reactive species. These cause cellular damage including components of the 
mitochondrial transport chain.35 L-NAME is being evaluated in animal models.5 
5. Monosialogangliosodes
Monosialogangliosodes are found in high concentrations in the brain and are important constituents of 
cellular  membranes.  GM1,  when  given  systemically,  incorporates  into  cellular  membranes  and 
enhances stabilization of membrane integrity and function, in experimental animal models.5
6. Growth factors
Nerve growth factor have been shown to reduce the severity of hypoxic-ischemic brain damage in 
immature experimental animal models.38
7. Glucocorticosteroids
Glucocorticoids have been used previously in human infants, children and adults to reduce the cerebral 
edema that arises from hypoxia-ischemia. Controlled clinical studies using low and high dose steroids 
suggest that the therapy is ineffective and that mortality in treated rat pups was greater than in control 
animals.35 
Barks et al35 have found a protective effect of dexamethasone in the immature rat when the drug was 
administered  > 24  hours  before  the  metabolic  insult.  Chumas  et  al39 showed  that  pretreatment  of 
immature rats with dexamethasone 6 hours before hypoxia-ischemia also provided protection with no 
infarction.
8. Phenobarbital
The mechanism of neuroprotection using short-acting barbiturates relates predominantly to an overall 
suppression  of  cerebral  oxidative  metabolism.  Barbiturates  also  blunt  cerebral  excitotoxicity  by 
depressing glutamate responses within the brain. Goldberg et al40 demonstrated in a clinical study that 
thiopental did not improve neonatal mortality or neurologic morbidity at 12 months of age. A recent 
clinical  trial  by Hall  et  al  demonstrated  beneficial  effect  with  high  dose  phenobarbital  therapy to 
severely asphyxiated newborn infants and is associated with significant improvement in neurologic 
outcome at 3 years of age.35
9. Fluid restriction
The  rationale  is  that  fluid  restriction  may limit  cerebral  oedema,  which  may be  important  in  the 
pathogenesis of brain damage after perinatal asphyxia. However, there is concern that excessive fluid 
restriction  may  cause  dehydration  and  hypotension,  resulting  in  decreased  cerebral  perfusion  and 
further brain damage.4  There are no RCTs on the effect of fluid restriction in newborn infants with 
perinatal asphyxia 
10. Hyperbaric oxygen treatment 
Hyperbaric oxygen is widely used for treating infants with hypoxic–ischaemic encephalopathy in China 
but is not a standard practice in other countries.
One systematic review found lower rates of mortality and adverse neurological outcomes in infants 
treated with hyperbaric oxygen. However, the RCTs included in the review used poor methods, and 
potential publication bias was reported. Therefore, the results should be interpreted with caution.4
11. Others 
Vitamin C and Vitamin E5
Nonpharmacologic interventions35
1. Hyperglycemia
2. Carbon Dioxide
3. Hypothermia
4. Hypoxic preconditioning
Gene therapy5
1. Apoptosis  inhibition  using  proto-oncogene  bcl-2,  originally  isolated  from  the  follicular 
lymphoma chromosomal translocation t(14:18)
2. Calbindin-D28k is  an intracellular  EF-hand calcium binding protein,  which acts  as a mobile, 
cellular  calcium buffer.  Bicistronic  defective  herpes  simplex  virus  vectors  that  encode  the 
calbindin-D28k gene are used.
Hypothermia 
Mechanism of action of Hypothermia
Brain  hypothermia  is  an example of  non-specific  neuroprotective  therapy signifying that  it  affects 
multiple  processes  in  the  events  leading  to  brain  injury.  A  relatively  small  reduction  in  brain 
temperature (1-6°C) of neonatal animals is associated with better maintenance of cerebral energy state 
during and immediately after ischemia, attenuation of the release of excitatory neurotransmitters, and 
decreased caspase-3 activation and morphologic evidence of apoptosis.23 Other neuroprotective effects 
of hypothermia include normalization of the decreased protein synthesis, reduction of free radicals and 
modulation of microglial activation and cytokine production.23 The net effect of modest hypothermia is 
an  attenuation  of  secondary  energy  failure  with  histopathologic  evidence  of  neuroprotection. 
Neuroprotection can be achieved when cooling is initiated at an interval of up to 5.5 hours after an 
hypoxic event.9,10
Hypothermia – History and animal trials
The first reports of hypothermia in newborns with birth asphyxia was reported by Westin41,42  in 1959 
and later  by Kopachev43 in Russia in the 1970’s but there  was no controlled evaluation.  Renewed 
interest in the use of hypothermia to reduce brain injury after ischemia was rekindled in the 1980s 
when experimental studies in dogs and rats showed that moderate levels of hypothermia (32-34 degrees 
C) during or following ischemia could be neuroprotective and improve neurological outcome.43 In the 
1990’s  the  principle  was  applied  to  fetal  sheep  model  of  cerebral  ischemia  by  Gunn  et  al5 and 
randomized controlled studies were performed later on newborn infants. 
Studies done in young adult dogs demonstrated that the success of neuroprotection with short durations 
of cooling during resuscitation whereas a delay of 15 minutes in initiation of cooling after reperfusion 
may not improve functional outcome although it may slightly decrease tissue damage.44 Studies done 
on the gerbil by Colbourne and Corbett clearly showed that mild postischemic hypothermia (34 degrees 
C, 1-25 hour postischemia) showed decreased neuronal damage histologically.45 The critical duration of 
cooling was also unknown. In the fetal sheep model of cerebral ischemia, Gunn et al demonstrated that 
moderate hypothermia between 30 and 33 degrees C for a period of 72 hours showed neuroprotection. 
There was an increase in damage if the hypothermia was started after 6 hours of the cerebral ischemia 
and  there  was  no  added  benefit  shown  if  the  hypothermia  was  extended  for  beyond  72  hours.10 
Investigations using newborn swine compared the difference in the brain temperature during head and 
body cooling.11 Head cooling performed with a constant rectal temperature increased the temperature 
gradient  across  the  brain  with  the  deep  brain  warmer  than  the  superficial  brain.  However,  brain 
hypothermia induced via body cooling to a rectal temperature of 34 degrees C, resulted in homogenous 
cooling  of  the  cerebral  cortex.  The  model  demonstrated  that  surface  cooling  reduces  deep  brain 
temperature only when core body temperature is lowered. Rectal temperature was found to be a valid 
index  of  brain  temperature  in  view of  the  small  temperature  gradients.  Whole  body cooling  also 
consistently reduced the cerebral  blood flow and the merabolic rate,  the latter  corretlated with the 
degree  of  temperature  drop.  The  effect  of  selective  brain  cooling  on  cerebral  blood  flow  is  less 
consistent.46 
The  cardiovascular  changes  that  occur  during  mild  therapeutic  hypothermia  include  minor  cardiac 
arrhythmias,  hypotension,  hemoconcentration,  sinus  bradycardia  and  peripheral  vasoconstriction.47 
Inadvertent  reduction in core temperature below the target  range occur  from active cooling and/or 
anticonvulsant/ sedative drugs necessitating active re-warming. Phenobarbitone or midazolam reduces 
the infant’s spontaneous activity and the decrease in muscular activity, which is an important source of 
heat production, causes the decrease in body temperature. Midazolam accentuated this tendency still 
further  by impairing thermoregulatory vasoconstriction.  There  was a  decrease  in  the mean arterial 
blood  pressure  associated  with  re-warming  but  not  associated  with  any  adverse  clinical  event. 
Benzodiazepine  drugs  facilitate  peripheral  vasodilatation  and  reduce  the  cardiac  output.  Rapid  re-
warming  leads  to  peripheral  vasodilatation  lowering  the  blood  pressure.  Re-warming  should  be 
conducted slowly at not >0.5°C per hour.48 Rapid increases in temperature during rewarming can cause 
cerebral edema with neurological deterioration.49 Increasing oxygen requirements during hypothermia 
was  probably  attributable  to  pulmonary  hypertension  or  impairment  of  pulmonary  surfactant  by 
hypothermia. Sinus bradycardia during hypothermia did not seem to have any clinical consequences, 
and no episodes of arrhythmia were detected. The heart rate rose to during passive re-warming to the 
normal range. Electrocardiographic changes noted are prolonged QT interval, a prolonged PR interval 
and Osborn waves.47 The low heart rate combined with increase stroke volume may be adequate for the 
reduced  metabolic  rate  during  hypothermia.48 The  cardiac  output  is  reduced  to  67%  of  the 
posthypothermic level. Skin perfusion was decreased but tissue perfusion was adequate as reflected by 
normal blood lactate levels.47
Coagulation abnormalities induced by mild hypothermia include platelet dysfunction and sequestration 
and enhanced fibrinolytic activity and physicochemical delay of the clotting cascade.47 The series of 
enzymatic reactions of the coagulation cascade are strongly inhibited by hypothermia, as demonstrated 
by the dramatic prolongation of prothrombin time and partial thromboplastin time tests at hypothermic 
deviations from normal temperature in a situation where factor levels were all known to be normal. 
This coagulopathy has a multifactorial origin.50
Thrombocytopenia  has  been  reported  in  moderate  hypothermia  in  adults  with  stroke.  This  was 
asymptomatic and there were no bleeding tendencies in any of the patients. 51
In newborn rabbits, a 2°C decrease in temperature was associated with a marked decrease in renal 
blood flow and glomerular filtration rate.52 In studies done in adults with stroke, moderate hypothermia 
caused no change in  urine output or creatinine clearance before,  during and after  the induction of 
hypothermia.51 Mild  hypokalemia  occured  during  hypothermia  and  is  thought  to  be  caused  by an 
intracellular shift of potassium. Excessive potassium supplementation must be avoided because of the 
risk of hyperkalemia during rewarming.53 There  were no changes in the serum sodium concentrations 
in studies done on adults.51 Hypothermia also affects the pH value, and for every 1°C decrease in body 
temperature, there is an increase of 0.016 points in the pH value.
Immunologic effects including impaired leukocyte mobility and phagocytosis are reported during mild 
hypothermia with a trend to increased sepsis, especially pneumonia in studies done on adults.51 Though 
there is  a  decrease in  the total  white  cell  count,  there  are  no reports  of  neutropenia  after  induced 
hypothermia.49
Gut motility is impaired during hypothermia and the combined effect of hypothermia and sedation may 
lead to paralytic ileus and patients may require total parenteral nutrition and delayed start of enteral 
nutrition. Because metabolic rate decreases by 7% for each 1°C decrease in body temperature, caloric 
intake needs to be adjusted accordingly.49 Hypothermia also decreases plasma insulin levels, and it has 
been hypothesized that this is secondary to catecholamine release. As a result, there is concomitant 
hyperglycemia,  and  exogenous  insulin  should  be  administered  in  patients  undergoing  induced 
hypothermia.54
Review of the human trials  with therapeutic hypothermia for newborn infants with hypoxia-
ischemia
A Cochrane meta-analysis  in October 2007, and republished in October 200855, had reviewed eight 
randomized control trials, comprising 638 term infants with moderate or severe encephalopathy with 
evidence of intrapartum asphyxia. Therapeutic hypothermia resulted in a statistically significant and 
clinically important  reduction in  the combined outcome of  mortality or  major  neurodevelopmental 
disability to 18 months of age [typical RR 0.76 (95% CI 0.65, 0.89), typical RD -0.15 (95% CI -0.24, 
-0.07), NNT 7 (95% CI 4, 14)]. Cooling also resulted in statistically significant reductions in mortality 
[typical RR 0.74 (95% CI 0.58, 0.94), typical RD -0.09 (95% CI -0.16, - 0.02), NNT 11 (95% CI 6, 
50)] and in neurodevelopmental disability in survivors [typical RR 0.68 (95% CI 0.51, 0.92), typical 
RD -0.13 (95% CI -0.23, -0.03)]. 
In the outcome of mortality, meta-analysis of the four trials (Gunn 199852 ; Akisu 200356 ; Gluckman 
200514; Lin 200615) that used selective head cooling with mild systemic hypothermia did not show a 
statistically significant effect on mortality [typical RR 0.83 (95% CI 0.59, 1.16), typical RD -0.05 (95% 
CI -0.14, 0.04)]. However, meta-analysis of the four trials that used whole body cooling (ICE 200258; 
Shankaran 200211; Eicher 200559,60 Shankaran 200517) demonstrated a significant reduction in mortality 
in the hypothermia groups [typical RR0.66 (95% CI 0.47, 0.93),  typical  RD -0.13 (95% CI -0.23, 
-0.02); NNT 8 (95% CI 4, 50)]. 
On assessment of major neurodevelopmental disability among survivors, meta-analysis of the two trials 
that  used selective head cooling with mild systemic hypothermia (Gunn 199852;  Gluckman 200514) 
failed to show a statistically significant effect [typical RR 0.77 (95% CI 0.51, 1.17), typical RD -0.09 
(95% CI -0.24, 0.05)]. However, meta-analysis of the two trials that used whole body cooling (Eicher 
200559,60 Shankaran  200517)  demonstrated  a  significant  reduction  in  major  neurodevelopmental 
disability among survivors in the hypothermia groups [typical RR 0.60 (95% CI 0.40, 0.92), typical RD 
-0.17 (95% CI -0.31, -0.03)]. 
Cardiovascular side effects 
Five trials reported effect on heart rate (Gunn 199852; Akisu 200356; Eicher 200559,60 Gluckman 200514 ; 
Shankaran  200517 ).  There  were  a  total  of  552 infants,  of  whom 26 had  sinus  bradycardia  below 
80/minute. Meta-analysis of the five trials demonstrated significantly increased sinus bradycardia in 
hypothermia groups [typical RR 5.96 (95% CI 2.15, 16.49), typical RD 0.07 (95% CI 0.04, 0.11)] 
(TABLE 01.16). Five trials reported the effect of hypothermia on the need for blood pressure support 
with inotropes (Gunn 199852;  ICE 200258;  Shankaran 200211;  Gluckman 200514;  Shankaran 200517). 
There were a total of 505 infants, of who 266 required inotrope support for hypotension. Meta-analysis 
of the five trials demonstrated an increase in hypotension treated with inotropes in hypothermia groups 
that was of borderline significance [typical RR 1.17 (95% CI 1.00, 1.38), typical RD 0.08 (0.00, 0.17)].
Six trials reported effect of hypothermia on cardiac arrhythmia requiring medical intervention and/or 
cessation  of  cooling  (Gunn  199852;  ICE  200258;  Akisu  200356;  Eicher  200559,60  Gluckman  200514; 
Shankaran 200517). There were a total of 569 infants, of whom 2 had an arrhythmia requiring medical 
intervention. Meta-analysis of the six trials failed to demonstrate a significant effect of hypothermia on 
arrhythmia requiring medical treatment in hypothermic groups [typical RR 1.04 (95% CI 0.07, 16.39), 
typical RD 0.00 (-0.02, 0.02)].
Haematological adverse effects 
Three trials reported the effect of hypothermia causing anaemia that required blood transfusion (Gunn 
199852;  Eicher  200559,60;  Gluckman  200514).  There  were  a  total  of  322 infants,  of  whom 39 were 
transfused  for  anaemia.  Meta-analysis  of  the  three  trials  failed  to  show  significant  effect  of 
hypothermia in causing anaemia requiring blood transfusion [typical RR 1.16 (95% CI 0.67, 2.04), 
typical RD 0.02 (95% CI -0.05, 0.09)] (TABLE 01.19). Two trials reported the effect of hypothermia 
on white cell count (Gunn 199852; Gluckman 200514). There were a total of 254 infants, of whom 6 had 
leukopenia with a white cell count below 5 x 109/L. Meta-analysis of the two trials failed to show 
significant effect of hypothermia on the incidence of leukopenia [typical RR 0.97 (95%CI 0.22, 4.33), 
typical RD0.00 (95%CI -0.04, 0.04)].
Four  trials  reported  the  effect  of  hypothermia  on  platelet  count  (Gunn  199852;  Eicher  200559,60; 
Gluckman  200514;  Shankaran  200517).  There  were  a  total  of  531  infants,  of  whom  124  were 
thrombocytopenic  with  platelet  count  below 150 x  109/L.  Meta-analysis  of  the  four  trials  showed 
statistically significantly increased thrombocytopenia in the hypothermia groups [typical RR 1.55 (95% 
CI 1.14, 2.11), typical RD 0.09 (95% CI 0.03, 0.15)].
Four  trials  reported  the  effect  of  hypothermia  on  coagulopathy  resulting  in  major  thrombosis  or 
haemorrhage (Gunn 199852; ICE 200258; Gluckman 200514; Shankaran 200517). There were a total of 
486 infants,  of  whom14 had severe  coagulopathy.  Meta-analysis  of  the  four  trials  failed  to  show 
significant  effect  on severe coagulopathy in  cooled  infants  [typical  RR 0.83 (95% CI 0.31,  2.24), 
typical RD -0.01 (95% CI -0.03, 0.02)].
Metabolic adverse effects
Four trials reported the effect of hypothermia on glucose homeostasis (Gunn 199852, Akisu 200356; 
Gluckman  200514;  Shankaran  200517).  There  were  a  total  of  490  infants,  of  whom  73  were 
hypoglycemic with a blood glucose below 2.6 mmol/L. Meta-analysis of the four trials failed to show 
significant hypoglycemia in hypothermic groups [typical RR 0.83 (95% CI 0.54, 1.27), typical RD 
-0.03 (95% CI -0.09, 0.03)] (TABLE 01.23). 
Three trials  reported the effect  of hypothermia on serum potassium (Gunn 199852;  Eicher 200559,60 
Gluckman 200514). There were a total of 323 infants, of whom 175 had hypokalemia with a serum 
potassium below 3.5  mmol/L.  Meta-analysis  of  the  three  trials  showed  no  statistically  significant 
difference in the incidence of hypokalemia in cooled infants [typical RR 1.03 (95% CI 0.85, 1.25), 
typical RD 0.02 (95% CI -0.09, 0.12)].
Renal impairment
Five trials reported the effect of hypothermia on urine output (Gunn 199852; ICE 200258; Shankaran 
200211;  Gluckman 200514;  Shankaran 200517). There were a total of 505 infants, of whom 147 had 
oliguria with urine output below1mL/kg/hour.Meta-analysis of the five trials showed no statistically 
significant difference in rate of oliguria in cooled infants [typical RR 0.81 (95% CI 0.59, 1.12), typical 
RD -0.05 (95% CI -0.12, 0.03)]. 
Sepsis
Five trials reported the effect of hypothermia on sepsis (Gunn 199852; Akisu 200356; Eicher 200559,60 
Gluckman 200514; Shankaran 200517). There were a total of 552 infants, of whom 28 had culture proven 
sepsis. Meta-analysis of the five trials failed to show a significant effect of hypothermia on sepsis 
[typical RR 0.86 (95% CI 0.42, 1.76), typical RD -0.01 (-0.04, 0.03)]. 
Implications for practice and policy
Most  of  these  trials  were  conducted  in  advanced neonatal  centers  in  industrialized  countries  with 
considerable experience in therapeutic hypothermia and the results might not be replicable to other 
settings. The extremely high cost of the equipment and the need to rigorously monitor and control the 
temperatures  further  limits  the  use  of  this  model  for  most  settings61 especially  in  resource  poor 
countries.
METHODOLOGY 
Population
Babies who were recruited into the trial included inborn (born at the Christian Medical College and 
Hospital) and outborn (born in a place other than the Christian Medical College and Hospital) admitted 
into the neonatal unit of the hospital. 
Inclusion and exclusion criteria for Inborn babies
Inclusion criteria
o Gestational age >35 wks 
o pH < 7.0 or base deficit > 12 in umbilical cord arterial blood sample or postnatal ABG within first 
hour of life AND 
o Any two of the following
o Apgar score < 5 at 5 minutes 
o Ventilation initiated at birth and continued for at least 10 minutes 
o History of acute perinatal event (any one) 
 Intrapartum fetal distress
 Cord prolapse 
 Placental abruption 
 Maternal respiratory arrest 
 Uterine rupture / dehiscence
Exclusion criteria
o Inability to start cooling the baby by 5.0 hours of age
o Small for gestational age babies (less than 10th centile for age)
o Chromosomal abnormality
o Major congenital anomaly 
o Refusal of consent for study participation
Inclusion and Exclusion criteria for Outborn babies
Inclusion criteria (all 3)
o Gestational age >35 wks 
o Babies who did not cry immediately after birth with any or all of the following features:
1. Not breathing normally at five minutes of birth
2. Given assistance for breathing during or soon after birth
3. Limp or flaccid since birth
4. Not sucking well at the breast since birth without any oro-facial abnormality if documented by a 
pediatrician
5. Apgar score of 5 or less at 5 minutes
o Evidence of encephalopathy
Exclusion criteria
o Inability to start cooling the baby by 5.0 hours of age
o Small for gestational age babies (less than 10th centile for age)
o Chromosomal abnormality
o Major congenital anomaly 
o Refusal of consent for study participation
NEONATAL INTENSIVE CARE UNIT
NEWBORN INFANT UNGERGOING WHOLE BODY COOLING
WBC MATERIAL: COOLING-GEL PACKS
RECTAL THERMOMETER PROBE
After obtaining informed consent from the parents, a neurological examination was done on infants 
included in the trial and they were categorized as having moderate or severe encephalopathy, using the 
modified Sarnat criteria. The infant was placed supine on cloth covered cooling gel-packs after the 
overhead warmer was switched off. A rectal probe to monitor temperature was inserted to 5 cm within 
the rectum and rectal temperature of 33 + 0.5°C was targeted. All infants had a central venous line and 
an arterial  access.  The temperature was continuously monitored and recorded.  The peripheral  skin 
temperature was measured simultaneously. When the infant’s rectal temperature increased to 33.5°C, 
more cloth covered cooling-gel packs were placed and they were removed when the rectal temperature 
reached 33°C. The room temperature was monitored.
The  vital  parameters  including  heart  rate  (electrocardiogram),  blood  pressure,  respiratory  rate  and 
transcutaneous oxygen saturation were monitored simultaneously and continuously. Blood gas analyses 
were  done  from  the  arterial  line.  The  infant  was  sedated  with  phenobarbitone  and  fentanyl,  if 
ventilation  was required  and sedation  withdrawn 8  hours  before  rewarming was started.  Inotropic 
agents  were  used  if  the  mean  arterial  pressure  was  less  than  the  gestational  age,  after  volume 
expansion. The infants were catheterized to monitor hourly urine output.
At the end of 72 hours of induced hypothermia, the radiant warmer was turned on to raise the body 
temperature by 0.5°C/hr to reach a target temperature of 36.5°C. The temperature probe was removed 
after monitoring the temperature for 80 hours after study initiation.
All treatment modalities including medications (antibiotics, anticonvulsants, paralytics), ventilation and 
blood products were used as the clinical condition demanded. 
The following laboratory parameters were monitored at regular intervals 
Additional blood gas analyses were done if there was a clinical  indication during this period.  Any 
deviation from the protocol was immediately informed to the investigator.
Labs Baseline 24 hours 48 hours 72 hours
S. Electrolytes
Blood urea
S. Creatinine
Blood lactate
SGOT/SGPT
Blood sugar
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
ABG √ 
0h
√ 
2h
√ 
8h
√ 
12h
√ √ √
PT/aPTT √ √ √
CBC √ √ √ √
Neurological 
examination √ √ √
Urine output Monitored hourly
ECG When clinically indicated (drop in the heart rate <80/mt)
The following were the adverse events that were monitored and reported to the investigator within 6 
hours of its occurrence
1. Cardiac arrhythmia (bradycardia of <80/minute, prolonged PR interval, prolonged QT interval, 
atrial fibrillation and Osborn or J waves) requiring medical treatment 
2. Persistent hypoxemia (transcutaneous oxygen saturation of 85% or a PaO2 <50 mm Hg inspite 
of a FiO2 of 1 on mechanical ventilation)
3. Hypotension despite full inotropic support (dopamine at an infusion rate of 10 μg/kg/min and 
dobutamine at an infusion rate of 20 μg/kg/min) 
4. Skin changes (sclerema, apostatonecrosis) 
5. Thrombocytopenia (<100,000/cumm) 
6. Life threatening coagulopathy (pulmonary and/or gastric and/or umbilical cord bleeding)
7. Arterial thrombosis
8. Hepatic and renal failure
9. Electrolyte disturbances
10. Death
Statistical analysis
The sample size was calculated using the design of Gehan (1961). With a 10% precision and a 20% 
desired effectiveness, the sample size was calculated as 20. The analysis of the data was done using the 
SPSS 16.0 software. Mean, median, mode, standard deviation, frequency were calculated. Tests for 
significance used were Pearson’s co-efficient and Mann-Whitney U test. The Kaplan-Meier graph was 
used to study the time-event survival analysis.
ANALYSIS AND RESULTS 
The study was done in the neonatology unit of the Christian Medical College and Hospital, Vellore 
over a period of 11 months. Twenty newborn infants were recruited into the study (9 inborns and 11 
outborns) after informed consent was obtained from the parents in the presence of the investigator. The 
babies were admitted to the neonatal intensive care unit and the cooling was started as per the protocol 
mentioned above. 
Plus–
minus values 
are means ±SD. 
Percentages are based on the number of infants for whom data were available.
Gravida – No. (%)
One 
Three
18 (90%)
02 (10%)
Complications of pregnancy – No. (%)
Gestational diabetes mellitus
Pregnancy induced hypertension
None
1 (5%)
2 (10%)
17 (85%)
Peripartum complications – No. (%)
Fetal Heart Rate Deceleration
Hemorrhage
Meconium Stained Amniotic Fluid
Details incomplete 
7 (77.7%)
1 (11.1%)
1 (11.1%)
11 
Onset of labour – No. (%)
Induced
Spontaneous
2 (10%)
18 (90%)
Duration of labour (in hours) 13 ± 10
Mode of delivery – No. (%)
Normal
LSCS
Forceps
Vacuum
9 (45%)
8 (40%)
2 (10%)
1 (5%)
Inborn - No. (%)
Outborn - No. (%)
9 (45%)
11 (55%)
TABLE 1: MATERNAL DEMOGRAPHICS
PERINATAL DEMOGRAPHICS
The perinatal demographics are mentioned in Table 1. Ninety percent of the newborns were born to 
primigravida mothers. All the mothers had regular antenatal care and only 3 (15%) had complications 
during  pregnancy.  Most  of  them  went  into  spontaneous  labour  and  9(45%)  had  intrapartum 
complications. The details of intrapartum complications in outborn deliveries were incomplete in 11 
cases. The mean duration of labour was 13 hours and 9 (45%) mothers had a vaginal delivery.
 Plus–minus values are means ±SD. 
Percentages are based on the number of infants for whom data were available.
Mean gestational age (wks) 38.5 ± 1.3
Age at starting cooling (hrs)
Inborn
Outborn
3.4 ± 1.2
3 ± 1
3.5 ± 1
Gender
Male
Female
Male (inborn:outborn) - No. (%)
Female (inborn:outborn) - No. (%)
8 (40%)
12 (60%)
4 (20%):4 (20%)
5 (25%):7 (35%)
Birth weight (gms) 3034 ± 518
Cord blood pH (inborn only) 6.945 ± 0.118
Cord blood BE (inborn only) -19.1 ± 3.2
Moderate encephalopathy - No. (%) 16 (80%)
Severe encephalopathy - No. (%) 4 (20%)
TABLE 2: NEONATAL DEMOGRAPHICS
NEONATAL DEMOGRAPHICS
The neonatal demographics are mentioned in Table 2.
All the babies were born at term with a mean gestational age of 38 weeks (range: 36.8-39.2 weeks). 
The mean age for starting cooling after birth was 3.4 hours (range: 2.2-4.6). Initiation of cooling inborn 
babies was faster than the outborns. There were 12 (60%) female infants and 8 (40%) male infants. The 
mean birth weight was 3034 gms (range: 2514-3538 gms). Cord blood pH and base excess details were 
available only for inborn babies.  The mean cord blood pH was 6.945 (range: 6.827-7.063) and the base 
excess was -19.1 (range: -15.9 to -22.3). Majority of the infants recruited had moderate encephalopathy 
according to the modified Sarnat staging. 
 
Plus–minus values are means ±SD. 
Percentages are based on the number of infants for whom data were available.
     TABLE 3B:  MANN-WHITNEY U TEST OF SIGNIFICANCE 
     (Comparison between time to achieve cooling vs other parameters)
 
Rectal temperature at start of cooling (°C) 36.0 ± 0.8°C
Skin temperature at start of cooling (°C) 35.8 ± 0.97
Time taken to reach target rectal temperature after initiation 
of cooling (minutes)
52 ± 25
No. who achieved target temperature within 1 hour of start 
of cooling (%)
13 (65%)
Time taken from birth to reach target temperature (minutes) 206 ± 63
Parameters p Value
Birth weight <0.05
Gestational age 0.877
Gender 0.536
Inborn vs Outborn 0.393
Induced labor vs Spontaneous 0.817
Mode of delivery 0.115
TABLE 3A: TEMPERATURE CHARACTERISTICS OF THE NEWBORNS
TEMPERATURE CHARACTERISTICS OF NEWBORNS
The temperature characteristics of the newborns are shown in Table 3. The mean rectal temperature at 
the start of cooling was 36°C (range: 35.2-36.8°C) while the mean skin temperature was 35.8°C (range: 
34.8-36.8°C). The mean time taken to reach target rectal temperature (32.5-33.5°C) was 52 minutes 
(range:  27-77  minutes).  Seven  babies  (35%)  achieved  target  rectal  temperature  after  one  hour  of 
initiation of cooling. The average room temperature was maintained between 28-30°C. (Table 3A)
TESTS OF SIGNIFICANCE
Pearson’s correlation looking at the linear relationship of birth weight and time taken to achieve target 
temperature  showed  a  positive  moderate  correlation  (r=0.545;  p<0.05)  which  was  statistically 
significant suggesting that the larger baby takes a longer time at school.
There was no statistical significance (using the Mann-Whitney U test) between time taken to cool and 
gestational age, gender, inborn or outborn, induced or spontaneous labor and mode of delivery. (Table 
3B)
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FIG. 1: TREND OF MEAN SKIN AND RECTAL TEMPERATURE DURING WBC
FIG. 2: TREND OF VARIATION IN MEAN RECTAL TEMPERATURE FROM TARGET 
TEMPERATURE DURING THE PERIOD OF COOLING
TREND OF MEAN SKIN AND RECTAL TEMPERATURE DURING WBC
The mean average rectal temperature during the period of cooling was between 32.8 and 33°C. The 
mean average skin temperature during the period of cooling was between 33 and 33.2°C. The mean 
average difference in the rectal and skin temperature was -0.15 ± 0.13°C. (Fig 1.)
TREND OF VARIATION IN MEAN RECTAL TEMPERATURE FROM TARGET TEMPERATURE 
DURING THE PERIOD OF COOLING
The variation in the mean rectal temperature from target temperature during the period of cooling was 
0.001 ± 0.11°C
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FIG. 4: MEAN VARIATION IN DIFFERENCE BETWEEN RECTAL AND SKIN TEMPERATURE 
DURING WBC
FIG. 3: MEAN VARIATION IN SKIN TEMPERATURE FROM THE TARGET TEMPERATURE 
DURING THE PERIOD OF COOLING
MEAN VARIATION IN SKIN TEMPERATURE FROM THE TARGET TEMPERATURE DURING THE 
PERIOD OF COOLING
The mean average difference between the target temperature and skin temperature during the period of 
cooling was -0.18 ± 0.14°C. (Fig. 3)
MEAN VARIATION IN DIFFERENCE BETWEEN RECTAL AND SKIN TEMPERATURE DURING 
WBC
The mean variation in the difference between rectal and skin temperature during the period of cooling 
is 0.18 ± 0.11°C. (Fig. 4)
    FIG. 5: KAPLAN-MEIER SURVIVAL ANALYSIS (TIME TO “EVENT”*)
* “Event” – achieving temperature of 32.5 – 33.5 °C
 Cum survival – Cumulative proportion of sample that did achieve event 
TIME TO EVENT ANALYSIS
The event  of  interest  is  rectal  temperature  of  32.5-33.5°C.  The  event  was  measured  for  every 15 
minutes for the first 4 hours and every one hour up to 80 hours. At the end of the first hour from 
commencement of cooling, only 35% of the newborn infants did not achieve the target temperature (ie 
did not attain the event). (Fig.5.)
At the end of 15 minutes,  30% achieved the target temperature;  the median time to event was 45 
minutes (95% CI 34.265-55.735). 
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FIG. 6: TREND OF MEAN HEART RATE DURING WBC
FIG. 7: TREND OF MEAN BLOOD PRESSURE DURING WBC
HEART RATE
The mean heart rate at the start of cooling was 138 per minute and the mean average heart rate during 
the period of cooling was 111 ± 5 per minute. (Fig. 6)
MEAN BLOOD PRESSURE
The mean blood pressure at the start of cooling was 54.7 mm Hg and the mean average mean blood 
pressure during the period of cooling was 55.6 ± 1.7 mm Hg. (Fig. 7) 
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FIG. 8: TREND OF MEAN OXYGEN SATURATION DURING WBC
OXYGEN SATURATION
The  mean oxygen  saturation  was  within  the  normal  range  through out  the  period  of  cooling  and 
rewarming. (Fig. 8)
2 HRS 8 HRS 12 HRS 24 HRS 48 HRS 72 HRS
pH 7.23±0.08 7.29±0.06 7.33±0.07 7.37±0.08 7.40±0.03 7.39±0.04
pCO2 38.6±11.3 36.8±8.7 37.3±5.4 36.2±12.5 38.2±6.4 38.9±8.6
pO2 89.9±38.9 86.3±48.3 108.9±95 96.9±47.8 107.7±66 93.1±24.8
HCO3- 15.6±4.7 17.3±4 19.1±2.8 20.5±5 22.5±3.2 22.5±2.5
BASE EXCESS -11.1±5.9 -7.3±5.9 -5.77±3.8 -3.1±6.36 -1.28±2.9 -1.1±3.8
O2 SATURATION 90.3±13.1 90.1±9.9 93±9.2 94.8±5.3 96.6±2 95.9±3
Plus–minus values are means ±SD. 
Percentages are based on the number of infants for whom data were available.
TABLE 4: ARTERIAL BLOOD GAS TREND OVER 72 HOURS
ARTERIAL BLOOD GAS TREND
Table 4 shows the arterial  blood gas trend over 72 hours of WBC. There was significant acidosis 
among inborn babies who had the cord blood pH and base excess done. The acidosis corrected within 
12 hours of the start of the procedure,  though 2 (10%) had persistent metabolic acidosis requiring 
sodabicarbonate infusion.  The serum bicarbonate levels also did not worsen on cooling but in fact 
increased to within normal limits within 2 hours and the base excess also corrected in 2 hours after the 
start of cooling. 
0 HRS 24 HRS 48 HRS 72 HRS
S. SODIUM (mEq/L) 134.5±4.8 133.7±4.8 134.8±4 135.9±6.7
S. POTASSIUM 
(mEq/L)
4.7±0.6 4.19±0.6 4.15±1 4.15±0.7
S. BICARBONATE 12.9±5.0 19.2±5.1 20.1±2.7 19.6±3.7
BLOOD UREA 19.7±5.7 26.4±11.8 23.3±11.7 19.6±12.2
S. CREATININE 0.9±0.1 0.8±0.4 0.6±0.2 0.5±0.1
BLOOD LACTATE 7.2±4.3 4.1±2.8 2.8±2.9 1.9±1.1
BLOOD SUGAR 103.1±53 153.8±143.2 102.4±65.8 90±34.1
 Plus–minus values are means ±SD. 
rcentages are based on the number of infants for whom data were available.
TABLE 5A: METABOLIC PARAMETER TREND OVER 72 HOURS
Plus–minus values are means ±SD. 
Percentages are based on the number of infants for whom data were available.
METABOLIC PARAMETERS
Table  5A  shows  the  biochemical  profile  of  the  newborn  infants  during  WBC.  The  electrolytes 
remained within normal limits during the cooling procedure. There was a mild increase in the blood 
urea after 24 hours of cooling, but this showed a down trend in the following hours. Serum creatinine 
and blood lactate showed a downward trend as the WBC progressed. The average blood sugars were 
within  the  normal  range.  However,  2  (10%)  had  hypoglycemia  and  3  (15%)  had  hyperglycemia 
requiring insulin. Liver enzyme levels were within normal limits (Table 5B). 
0 HRS 24 HRS 48 HRS 72 HRS
AST (IU/L) 129.4±112.3 155.8±188 142.1±260 68.5±31.8
ALT (IU/L) 47.8±67.3 64.5±69.3 85.4±88 56±65.2
TABLE 5B: HEPATIC ENZYME TREND OVER 72 HOURS
0 HRS 24 HRS 48 HRS 72 HRS
HB (g/dL) 17±1.8 16.1±3.4 16.2±2 15.8±2.1
PCV 52±5.1 49.6±5.3 43.5±11.9 47.5±4.8
TOTAL WBC COUNT(/cmm) 23015.7±9861 14818±5527 11351±3117 9669±3021
NEUTROPHIL (%) 69±15 85±9 76±9 67±10
PLATELET COUNT (/cmm) 200850±53817 165055±45304 145263±50675 127894±45077
PT (sec) 20.59±10.5 24±23.4 12.76±1.9
INR 2±1.9 1.9±1.9 1±0.1
PTT (sec) 63.2±43 58.8±30.9 49.8±9.8
Plus–minus values are means ±SD. 
Percentages are based on the number of infants for whom data were available.
HEMATOLOGY TREND 
ble 6 show the hematology trend over 72 hours of WBC. The hemoglobin and the packed cell volume 
dropped marginally during the WBC. The total white cell count showed a decreasing trend and there 
was no neutropenia. The platelet count also showed a decreasing trend during the procedure. The PT 
and the INR which was prolonged at  the start  of  cooling got worse at  24 hours and subsequently 
improved. The aPTT which was impaired at the initiation of cooling showed an improving trend over 
72 hours.
TABLE 6: HEMATOLOGY TREND OVER 72 HOURS
MEDICATION NO (%)
Anticonvulsants 12 (60%)
Saline bolus 11 (55%)
Inotropes 16 (80%)
Insulin 3 (15%)
Fresh Frozen Plasma 6 (30%)
Sodabicarbonate 2 (10%)
Ranitidine 1 (5%)
Plus–minus values are means ±SD. 
Percentages are based on the number of infants for whom data were available.
MEDICATIONS USED 
Medications used during WBC are shown in Table 7. Twelve (60%) infants required anticonvulsants 
for seizure control. Phenobarbitone, phenytoin and midazolam were the anticonvulsants used. Saline 
boluses were given to 11 (55%) babies for acidosis and hypotension. Sixteen (80%) infants required 
inotropic support for which dopamine and dobutamine were used. Fresh frozen plasma for prolonged 
coagulation profile was required in 6 (30%) of newborns. Hyperglycemia requiring insulin was seen in 
3 (15%) babies. Persistent acidosis requiring sodabicarbonate infusion was started in 2 (10%) infants. 
Ranitidine for altered blood through the nasogastric feeds was required for 1 (5%) baby.
TABLE 7: MEDICATIONS USED DURING WBC
ADVERSE EVENTS NO (%)
Cardiac arrhythmias Nil
Hypoglycemiaф  2 (10%)
Hyperglycemia requiring insulin∆ 3 (15%)
Thrombocytopenia¶ (< 100000/cmm) 5 (25%)
Bleeding§ 1 (5%)
Skin changesψ 3 (15%)
Hypoxemia⌂ 1 (5%)
Hepatic dysfunction# 1 (5%)
Oliguria* 1 (5%)
Persistent acidosis† requiring sodabicarbonate infusion 2 (10%)
Death 1 (5%)
Ф Hypoglycemia defined as plasma sugar < 45mg/dL or blood sugar <50 mg/dL
∆ Hyperglycemia defined as plasma sugar >150 mg/dL or blood sugar > 175mg/dL
§ Bleeding was defined as overt bleeding with a platelet count of less than 40,000 per liter with abnormal results on 
coagulation studies
¶ Thrombocytopenia did not cause clinical bleeding, except in one baby who had DIC
Ψ Aposteatonecrosis was seen in 3 babies that resolved spontaneously
⌂ Hypoxemia defined as transcutaneous oxygen saturation of 85% or a PaO2 <50 mm Hg inspite of a FiO2 of 1 on 
mechanical ventilation
# Hepatic dysfunction defined as AST >200 and ALT >100 
* Oliguria defined as <0.5 ml/kg/hr
† Persistent acidosis is defined as acidosis persisting 3 hours after the start of intervention
Percentages are based on the number of infants for whom data were available.
TABLE 8: SERIOUS ADVERSE EVENTS DURING WBC
SERIOUS ADVERSE EVENTS 
Serious  adverse  events  that  occurred  during  WBC  are  seen  in  Table  8.   There  were  no  cardiac 
arrhythmias  recorded  during  WBC.  There  were  5  (25%)  babies  who  developed  transient  sinus 
bradycardia, defined as heart rate <80 beats/minute. There were no systemic effects and no medication 
was required. ECG was done to look for the presence of J waves and there were none. Hypoglycemia, 
defined as blood sugar < 50mg/dL, was seen in 2 (10%) of babies which required a higher infusion of 
carbohydrates. Hyperglycemia requiring insulin, defined as plasma sugar > 150 mg/dL, was seen in 3 
(15%) babies. Thrombocytopenia, defined as platelet count < 100000/cmm, were seen in 5 (25%) of 
newborn infants during the WBC. Infants who had thrombocytopenia at the start of WBC have not 
been included, as the thrombocytopenia was attributed to the bone marrow involvement secondary to 
hypoxia.  Bleeding  requiring  transfusions  was  seen  in  1  (5%)  infant.  Skin  changes  (sclerema  or 
aposteatonecrosis) were noted in 3 (15%) of infants and there was spontaneous resolution of the same 
during  the  recovery  period.  Hypoxemia  requiring  ventilatory  support  was  seen  in  1  (5%)  infant. 
Hepatic dysfunction, defined as AST >200 and ALT >100, was seen in 1 (5%) infant. Oliguria, defined 
as urine output < 0.5 ml/kg/hr, was seen in 1 (5%) infant. One infant died during WBC. This infant had 
prolonged bleeding parameters and a subgaleal bleed that worsened with cooling. Neurosonogram was 
done on all infants who underwent WBC, within the first week. One (5%) showed periventricular white 
matter changes while the rest were normal.
DISCUSSION
Hypothermia has been widely studied as a neuroprotective strategy in newborn and adult animals after 
ischemia and hypoxia-ischemia. In perinatal animals (sheep, rats and piglets), hypothermia was found 
to be beneficial when implemented within 5.5 hours of brain ischemia.10 Studies done in many of the 
developed countries using expensive equipment for whole body cooling or selective head cooling was 
found to be beneficial in terms of the reduction of mortality and long term morbidity.13,17 This trial was 
done in a developing country to look at the feasibility of obtaining consent and achieving the target 
temperature within one hour of initiation and within 6 hours of birth, maintaining the target temperature 
for 72 hours and to look at adverse events and complication that could occur in our population and 
setting.
The sample size was calculated using the design of Gehan (1961). With a 10% precision and a 20% 
desired effectiveness, the sample size was calculated as 20. The analysis of the data was done on the 
SPSS  16.0  software.  Mean,  median,  mode,  standard  deviation,  frequency,  Pearson’s  co-efficient, 
student t test and the Kaplan-Meier graph were used.
Inclusion criteria
This  trial  was  designed  to  include  infants  with  moderate  or  severe  encephalopathy  based  on  the 
modified Sarnat staging.  Twenty newborn infants were recruited into the trial  over a period of 11 
months after fulfilling the eligibility criteria. Most other studies on hypothermia for perinatal asphyxia 
included babies with similar clinical profile to ours.13-15,17 Some studies in addition have included aEEG 
as part of the inclusion criteria hoping to improve the specificity of brain injury.62 A control arm was 
not  included  in  this  study  as  this  was  a  feasibility  trial  and  it  was  felt  that  the  efficacy  of  the 
intervention had already been proved in randomized control trials and published data make it unethical 
to deny cooling to any infant.
Method and duration of cooling and rewarming
Cloth covered ice-gel packs were used as the cooling agent with the skin and the rectal temperature 
being monitored closely. This was an innovative method as trials in most of the developed countries 
used  expensive  equipment.  Continuous  monitoring  of  the  vital  parameters  was  done  using  multi-
parameter monitors. The target temperature in this trial was a rectal temperature of 32.5-33.5°C. The 
target temperature in other trials and the methods of cooling are mentioned in Table 9. The temperature 
range used in this trial is termed moderate hypothermia. The duration of hypothermia was 72 hours in 
our study as it was in all the other trials. Four studies used head cooling devices in conjunction with 
whole body cooling (Gunn 199852; Akisu 200356; Gluckman 200514; Lin 200615), while the other four 
used whole body cooling alone (Shankaran 200211;  ICE 200258;  Eicher 200559,60 Shankaran 200517). 
The duration of hypothermia was 72 hours in all but one study that cooled infants for 48 hours (Eicher 
200559,60).  The rewarming period was by 0.5°C per hour as in other trials.    Six studies rewarmed 
infants by 0.5 degrees Celsius per hour with the rewarming period of four hours (Akisu 200356; Eicher 
200559,60;Gluckman 200514 ; Gunn 199852 ; Shankaran 200211; Shankaran 200517), one study rewarmed 
infants by 0.5 degrees Celsius every second hour with a duration of 8 hours for rewarming (ICE 200258) 
and one study allowed infants to rewarm spontaneously at room temperature, such that rewarming took 
up to 12 hours (Lin 200615).
The  cost  of  whole  body  cooling  apparatus  with  a  reservoir  and  blanket  was  US$  13,185.00 
(Hemotherm dual reservoir (400 MR). Nicola JR et al63 published data of their trial done in a low 
resource setting in Uganda between July and October 2007. They used low cost resources to achieve 
whole body cooling, including a mattress made of commercially available water bottles laid sideways 
in the cot and filled with cool water from the tap in the neonatal unit. The target temperature for this 
trial was a rectal temperature of 33-34°C. The material use in our study was available free of cost as 
part of the packing material of vaccine transport. 
TABLE 9: IMPORTANT CHARACTERISTICS OF OTHER TRIALS TILL DATE
Method of cooling Target temperature Rewarming 
protocol
Duration of cooling
Akisu 200356 Servo controlled Cooling Cap Rectal temp: 36-36.5°C 72 hours
Left EAC temp: 33-33.5°C
Eicher 200559,60 Ice to head and body for 2 hours and 
servo controlled cooling blanket
Rectal temp: 32.5-33.5°C 0.5°C/hour 48 hours
Gluckman 200514 Servo controlled cooling cap Rectal temp: 34-35°C 0.5°C/hr 72 hours
Gunn 198852 Cooling cap 3 groups  with  rectal  temp 
in  (i)  36-36.5°C  (ii) 
35.5-35.9°C  (iii) 
34.5-35.4°C
72 hours
ICE 200258 Hot/Cold Gel packs Rectal temp: 33.5-34.5°C 0.5°C/2hours 72 hours
Lin 200615 Cooling cap Rectal temp: 34-35°C Rewarm 
spontaneously  to 
room temperature
72 hours
Shankaran 200211 Servo controlled cooling blanket Oesophageal temp: 34.5°C 0.5°C/hour 72 hours
Shankaran 200517 Blanketrol  II  Hyper-Hypothermia 
System
Oesophageal  temp: 
33-34°C
0.5°C/hour 72 hours
Nicola JR 200863 Water bottles with cool tap water Rectal temp: 33-34°C 72 hours
It was also possible to obtain an informed consent and initiate treatment within 5 hours of birth in both 
inborn and outborn infants. The mean time to achieve target temperature in our study was 52 ± 25 
minutes (range 15 to 105 minutes). In a similar study done in China it took 55 ± 20 minutes to reach 
target temperature.15 Although many of the studies do not give the data on how long it took to cool the 
infants  to  the  target  temperature,  available  data  suggest  that  upper  limit  of  90  minutes  is  more 
feasible.17 Though  only 65% were  cooled  in  our  trial  within  one  hour,  using  this  criterion  of  90 
minutes, 95% of our newborn infants reached the target rectal temperature. 
An undulating pattern of temperature may not only increase the adverse effects of cold exposure when 
at the lowest point of temperature fluctuation but also compromise the degree of neuroprotection at the 
peak temperature because even small changes (as little as 1-2°C) in brain temperature may modulate 
the extent of hypoxic ischemic damage. In this trial the mean variation in the rectal temperature was 
only 0.001 ± 0.18°C from the mean target temperature of 33°C. 
The mean skin temperature was 33.1 ± 0.14°C during the period of cooling as compared to the mean 
temperature during the trial by Shankaran of 31.9 ± 1.4°C.17 The mean average difference between the 
target temperature and skin temperature during the period of cooling was -0.18 ± 0.14°C. The relative 
constant skin temperature in relation to  the rectal  temperature implies that  the skin temperature is 
comparable with the rectal temperature.  
In  developing  countries  where  there  are  technical  difficulties  in  a  constant  monitoring  of  rectal 
temperature, monitoring of the skin temperature may be adequate. During the initiation of the cooling, 
multiple cloth covered ice-gel packs were used till the target temperature was achieved. After attaining 
the target temperature, the number of ice-gel packs used to maintain the target temperature for the next 
72  hours  were  very minimal.  The  babies  tend  to  maintain  the  temperature  without  any difficulty. 
However,  large  for  date  babies  required  more  cloth  covered  ice-gel  packs  to  maintain  target 
temperature. In developing countries which cannot afford high technology equipment, this study proves 
that simple cloth covered ice-gel packs with good nursing care and monitoring of the skin temperature, 
is practical. There was no requirement for servo-controlled blankets, manual adjustments of the water 
temperature of the cooling cap and output of the overhead heater or complex adjustments of the air 
temperature. The inability to cool 7 infants within the target time was attributed to the birth weight, 
nursing protocol and the absence of the investigator on site. The 7 babies had a mean birth weight 
exceeding 3000 gms and took a mean time of 82 minutes to cool. The investigator was not available on 
site for 4 of these babies. Two of the babies were started on the cooling protocol during the nursing 
shift  resulting  in  inadequate  monitoring.  This  was  seen  half  way through  the  study and  required 
additional protocols were implemented to rectify the same. 
Two inborn  babies  who fulfilled the  eligibility criteria  could  not  be recruited  into  the trial  as  the 
investigator was informed after the target time of 5.0 hours of birth. Three outborn babies who fulfilled 
the eligibility criteria could not be included in the trial as they arrived at the hospital after 5.0 hours of 
life.  
 
TABLE 10: COMPARISON OF SERIOUS ADVERSE EVENTS WITH OTHER PUBLISHED TRIALS
Adverse events Gluckmann 
200514
(n = 112)
Gunn 199852
(n=13)
Shankaran 
200211
(n =9)
Shankaran 200517
(n=103)
WBC 
2008
Cardiac 
arrhythmias
0 (0%) 1 (7.6%) 0 2 (1.9%) 0 (0%)
Hypoglycemia 14 (13%) 3 (23%) - 12 (11.6%) 2 
(10%)
Hyperglycemi
a
- - - - 3 
(15%)
Bleeding 1 (0.8%) 4 (31%) 1 (11.1%) 3 (2.9%) 1 (5%)
Skin changes 1 (0.8%) - - 4 (3.8%) 3 
(15%)
Hypoxemia - 4 (31%) 3 (33.3%) 25 (23.1%) 1 (5%)
Hepatic 
dysfunction
42 (38%) 0 1 (11.1%) 20 (19.4%) 1 (5%)
Persistent 
acidosis
22 (20%) 0 2 (1.9%) 2 
(10%)
Death 36/108 (33%) 1 (7.6%) 2 (22.2%) 45 (44%) 1 (5%)
Adverse events Gluckmann
200514
(n = 112)
Gunn 
199852
(n=13)
Shankaran
200211
(n =9)
Shankaran
200517
(n=103)
ICE
200258
(n=7)
Akisu
200356
(n=11)
WBC 2008
(n=20)
Sinus bradycardia 10 (8.9%) 1 (7.6%) - 1 (0.9%) 0 (0%) 5 (25%)
Hypotension 
(requiring  inotropic 
support)
74 (66%) 3 (23%) 5 (28.8%) 55 (53%) 3 (42.8%) - 17 (35%)
Anemia  requiring 
transfusion
5 (4.4%) 2 (15%) - - - - 0 (0%)
Leukopenia 2 (1.7%) 1 (7.6%) - - - - 0 (0%)
Thrombocytopenia 39 (34.8%) 7 (53.8%) - 3 (2.9%) - - 5 (25%)
Coagulopathy  with 
hemorrhage
0 (0%) 2 (15%) - 3 (2.9%) 1 (14.2%) - 1 (5%)
Hypokalemia 71 (63.3%) 8 (61.5%) - - - - 0 (0%)
Sepsis 3 (2.6%) 1 (7.6%) - 5 (4.8%) - 1 (9%) 0 (0%)
Oliguria 24 (21.4%) 13 (100%) 3 (33.3%) 24 (23%) 3 (42.8%) - 1 (5%)
The results of this feasibility trial agreed with other pilot studies that hypothermia is not associated with 
adverse events like cardiac arrhythmias, prolonged acidosis, life threatening bleeding or thrombosis. 
The  fall  in  the  heart  rate  when the  rectal  temperature  was lowered  to  the  target  temperature  was 
consistent with other reports and the physiologic effects of cold. The mean blood pressure increased 
after the initiation of whole body cooling and decreased to normal levels after the baby was re-warmed. 
 The biochemical and hematological parameters were monitored over the 72 hours of cooling. There 
was no evidence of anemia requiring transfusions or hemoconcentration in any of the newborn infants. 
There was thrombocytopenia in five of the infants that could be attributed to cooling. However, there 
was no significant clinical bleeding in 4 of the babies. One baby who had deranged coagulation profile 
before the start of cooling had developed disseminated intravascular coagulation with a subgaleal bleed 
to which he succumbed. There was no leucopenia or neutropenia that was noted. Though immunologic 
effects due to impaired leucocyte mobility and phagocytosis were noted in adult studies, there was no 
evidence of sepsis in any of the newborn infants who underwent whole body cooling. There was no 
TABLE 11: COMPARISON OF MINOR ADVERSE EVENTS WITH OTHER PUBLISHED TRIALS
evidence of hypokalemia and persistent metabolic acidosis. Hypoglycemia was seen in two infants 
requiring higher carbohydrate content. They returned to normal levels after re-warming and did not 
require any further interventions. Hyperglycemia requiring insulin was seen in three babies. This was 
attributed to the decrease in insulin secretion during hypothermia. This effect has not been seen in any 
of the other trials involving newborn infants. Hepatic dysfunction was noted in most babies before the 
initiation of cooling and this was attributed to the hypoxic ischemic damage. However, one infant who 
had normal liver enzymes at the start of WBC, showed a worsening trend as the cooling progressed. 
This was not clinically significant and returned to normal levels prior to discharge. Blood lactate levels 
showed  a  downward  trend  suggesting  that  moderate  hypothermia  does  not  increase  anaerobic 
metabolism in the cells.
The skin changes were noted specifically as cloth covered ice-gel packs were used in the initiation and 
maintenance of cooling. During the start of cooling, there was hyperemia in the areas where the ice-gel 
packs  were placed and this  required frequent  rotation of  the packs to  different  areas  of the body. 
However, during the maintenance phase, the number and duration of application of the ice-gel packs 
was very minimal and there were no skin changes noted during this phase. The aposteatonecrosis that 
occurred in three babies occurred during the start of cooling. These changes subsequently resolved 
without any intervention and without scarring. 
Death occurred in one infant who was born with a large subgaleal hemorrhage. The baby also had 
prolonged coagulation parameters at birth with thrombocytopenia that occurred after the initiation of 
cooling. The bleed into the subgaleal space worsened during the whole body cooling. The condition of 
the child was informed to the investigator who met with the committee monitoring adverse events. The 
baby was started on the rewarming protocol after 27 hours of hypothermia.  The small sample size 
precludes any definite conclusion on adverse events. We demonstrated a good correlation between the 
rectal temperature and the skin temperature in babies who were cooled. However, this may not be a 
true correlation as the numbers studied were small.   
This feasibility trial in a developing country using low cost cooling techniques and careful monitoring 
of temperature, establishes that this neuroprotective strategy can be used in peripheral hospitals that 
have a neonatal care unit. This neuroprotective strategy will help decrease the mortality and morbidity 
of neonatal infants born with perinatal asphyxia and will improve the quality of life of these infants.
CONCLUSIONS
The conclusions of this feasibility trial are 
1. In a low resource setting, it is feasible to 
• Obtain an informed consent and start the procedure within the acceptable time-frame of 
6 hours following birth.
• Achieve  a  target  rectal  temperature  within  6  hours  of  birth  and  90  minutes  of 
commencement of whole body cooling.
• Maintain the target rectal temperature for 72 hours.
2. Low-cost, easily available and reusable materials like cloth covered ice-gel packs are sufficient 
for achieving and maintaining the target rectal temperature. 
3. Constant  and  careful  monitoring of  the  skin temperature  may be adequate  in  low resource 
centers.
4. There were only minimal serious adverse events during this procedure.
• Newborn  infants  who  have  deranged  coagulation  parameters  with  obvious  signs  of 
bleeding should probably be excluded from the cooling process.
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